Gilead Sciences (GILD) CFO sells 3,000 shares in pre-set 10b5-1 plan

Rhea-AI Filing Summary

Gilead Sciences Chief Financial Officer Andrew D. Dickinson carried out an open-market sale of 3,000 shares of common stock on July 15, 2026 at an average price of $129.9256 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan, and he continues to hold 168,646 shares directly.

Insider Trade Summary 10b5-1

Net Seller: 3,000 shares ($389,777)

Net Sell 1 txn

Insider Dickinson Andrew D

Role Chief Financial Officer

Sold 3,000 shs ($390K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,000	$129.9256	$390K

Holdings After Transaction: Common Stock — 168,646 shares (Direct)

Footnotes (1)

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Sale prices for the transactions reported range from $129.45 to $130.08. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

Key Figures

Shares sold: 3,000 shares Average sale price: $129.9256 per share Holdings after transaction: 168,646 shares +1 more

4 metrics

Shares sold 3,000 shares Open-market sale of common stock on July 15, 2026

Average sale price $129.9256 per share Price received in the reported open-market sale

Holdings after transaction 168,646 shares Directly held Gilead Sciences common stock following the sale

Sale price range $129.45–$130.08 per share Range of prices for individual trades within the reported sale

Key Terms

Rule 10b5-1 trading plan, open-market sale, non-derivative, beneficial ownership

4 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action":"open-market sale" for the non-derivative common stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

non-derivative financial

"transaction_type":"non-derivative" indicating common stock rather than options or other derivatives"

beneficial ownership financial

"information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/16/2026 - 06:08 PM Accepted by SEC EDGAR 07/16/2026 - 06:08 PM Learn about SEC filing dates

FAQ

What insider transaction did Gilead Sciences (GILD) report for its CFO?

Gilead Sciences reported that CFO Andrew D. Dickinson sold 3,000 shares of common stock in an open-market sale on July 15, 2026. The average sale price was $129.9256 per share, and the transaction was made under a Rule 10b5-1 trading plan.

How many GILD shares does the CFO hold after this Form 4 transaction?

After the reported sale, CFO Andrew D. Dickinson holds 168,646 Gilead Sciences common shares directly. This reflects his position following the 3,000-share open-market sale disclosed, indicating he retains a substantial continuing equity stake in the company.

At what price did the GILD CFO sell the 3,000 shares reported on Form 4?

The 3,000 Gilead Sciences shares were sold at an average price of $129.9256 per share. Footnote disclosure states individual sale prices ranged from $129.45 to $130.08, with full trade-level details available to regulators and shareholders upon request.

Was the Gilead Sciences (GILD) CFO sale made under a Rule 10b5-1 plan?

Yes. The filing notes the sale was executed under a Rule 10b5-1 trading plan adopted on August 29, 2024. Such pre-arranged plans automate trades, meaning the timing of this 3,000-share sale was predetermined rather than a discretionary market decision.

What type of security was involved in the GILD CFO’s Form 4 transaction?

The transaction involved Common Stock of Gilead Sciences. It was reported as a non-derivative open-market sale, code “S,” meaning it did not involve options or other derivatives, and directly reduced the CFO’s common share holdings by 3,000 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dickinson Andrew D

(Last) (First) (Middle)

GILEAD SCIENCES, INC.

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		S(1)		3,000	D	$129.9256(2)	168,646	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

2. Sale prices for the transactions reported range from $129.45 to $130.08. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

Remarks:

	/s/ Amy Kim by Power of Attorney for Andrew D. Dickinson	07/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)